These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32952)

  • 1. Aetiology and natural history of Parkinson's disease.
    Pearce JM
    Br Med J; 1978 Dec; 2(6153):1664-6. PubMed ID: 32952
    [No Abstract]   [Full Text] [Related]  

  • 2. Understanding Parkinson's disease.
    Youdim MB; Riederer P
    Sci Am; 1997 Jan; 276(1):52-9. PubMed ID: 8972618
    [No Abstract]   [Full Text] [Related]  

  • 3. [Drug therapy in Parkinson's disease].
    van Hilten JJ; Roos RA
    Ned Tijdschr Geneeskd; 1999 Jan; 143(5):234-40. PubMed ID: 10086151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [L-dopa-resistant Parkinson's disease with cerebral atrophy: striato-nigral degeneration?].
    Dell'Aria V; Ciannella L; Melone MA
    Acta Neurol Quad (Napoli); 1981; 42():212-5. PubMed ID: 7270052
    [No Abstract]   [Full Text] [Related]  

  • 5. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [ Is Parkinson's disease due to deficiency of dopamine?].
    Castrén E
    Duodecim; 2005; 121(7):782-3; author reply 783-4. PubMed ID: 15909967
    [No Abstract]   [Full Text] [Related]  

  • 7. [Will the mystery of Parkinson's disease be resolved?].
    Lyytinen J; Kaakkola S
    Duodecim; 2005; 121(3):275-84. PubMed ID: 15787285
    [No Abstract]   [Full Text] [Related]  

  • 8. Parkinson's disease and levodopa. A five-year follow-up and review.
    Markham CH; Treciokas LJ; Diamond SG
    West J Med; 1974 Sep; 121(3):188-206. PubMed ID: 4606887
    [No Abstract]   [Full Text] [Related]  

  • 9. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
    Hornykiewicz O
    Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current views on Parkinson's disease.
    Calne DB
    Can J Neurol Sci; 1983 Feb; 10(1):11-5. PubMed ID: 6132677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal ganglia disease.
    Marsden CD
    Lancet; 1982 Nov; 2(8308):1141-7. PubMed ID: 6128460
    [No Abstract]   [Full Text] [Related]  

  • 12. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?
    Agid Y; Graybiel AM; Ruberg M; Hirsch E; Blin J; Dubois B; Javoy-Agid F
    Adv Neurol; 1990; 53():83-100. PubMed ID: 1978522
    [No Abstract]   [Full Text] [Related]  

  • 13. [What is the Best Initial Treatment for Parkinson's Disease? New Clinical Practice Guideline and My Personal Opinion].
    Takeda A
    Brain Nerve; 2019 Aug; 71(8):857-867. PubMed ID: 31346142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease.
    Marsden CD
    Postgrad Med J; 1992 Jul; 68(801):538-43. PubMed ID: 1437950
    [No Abstract]   [Full Text] [Related]  

  • 15. Asymmetry of substantia nigra neuronal loss in Parkinson's disease and its relevance to the mechanism of levodopa related motor fluctuations.
    Kempster PA; Gibb WR; Stern GM; Lees AJ
    J Neurol Neurosurg Psychiatry; 1989 Jan; 52(1):72-6. PubMed ID: 2709038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential nondopaminergic drugs for Parkinson's disease.
    Silverdale MA; Fox SH; Crossman AR; Brotchie JM
    Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of PET in Parkinson's disease.
    Shinotoh H; Calne DB
    Brain Cogn; 1995 Aug; 28(3):297-310. PubMed ID: 8546856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The nigrostriatal system in Parkinson's disease.
    Graybiel AM; Hirsch EC; Agid Y
    Adv Neurol; 1990; 53():17-29. PubMed ID: 1978514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the nigrostriatal dopaminergic neurons in mediating the effect of exogenous L-dopa in Parkinson's disease.
    Melamed E
    Mt Sinai J Med; 1988 Jan; 55(1):35-42. PubMed ID: 3279303
    [No Abstract]   [Full Text] [Related]  

  • 20. [L-dopa-resistant parkinsonism with cerebral atrophy: striato-nigral degeneration? 2 cases].
    Dell'Aria V; Ciannella L; Melone MA
    Acta Neurol (Napoli); 1981 Feb; 3(1):212-5. PubMed ID: 7246294
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.